Who Is the Best Suitor for Onyx Pharmaceuticals, Inc. (ONXX)?

Page 1 of 2

Cancer-drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen, Inc. (NASDAQ:AMGN). Onyx also said that it is looking for potential suitors. The move has triggered speculations of a bidding war, sending the stock up 51.27% on Monday to $131.33.

Amgen, Inc. (NASDAQ:AMGN) had offered to pay $120 per share in cash, a 38.2% premium to Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s closing price of $86.82 on Friday, June 28. However, Onyx CEO Dr. Tony Coles felt that Amgen’s bid significantly undervalued his firm.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

Onyx has an envious product portfolio

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) makes cancer drugs that generate high margins. It has liver- and kidney-cancer drug Nexavar, colon-cancer drug Stivarga and the newly launched Kyprolis. Analysts believe annual sales of Kyprolis could reach $3 billion. The peak sales of Nexavar and Stivarga could reach $1.4 billion and $1 billion, respectively. While Nexavar is established in the market, the other two drugs are yet to reach their sales peak. Onyx also has several promising drugs in the pipeline.

Large pharmaceutical companies have been eyeing cancer drugs because they require small sales forces and are usually covered by medical insurers. The potential acquirer has to take a bullish view on the future sales of Nexavar and Kyprolis. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s breast cancer molecule palbociclib has also showed promising results. The company has licensed palbociclib to Pfizer, for which it would get an 8% global royalty when the product hits the market.

Amgen is desperate for acquisitions

Amgen, Inc. (NASDAQ:AMGN) plans to expand its business overseas and add new products to its portfolio as sales of its blockbuster drugs Aranesp and Epogen continue to decline. These two anemia drugs generated about $4 billion in sales in 2012. Moreover, some of Amgen’s major drugs will witness patent expiry starting 2015.

Amgen, Inc. (NASDAQ:AMGN) is planning to launch as many as six biosimilars by 2017. Kyprolis could complement Amgen’s product portfolio of cancer drugs and benefit from Amgen’s sales and marketing infrastructure. However, equity research firm ISI Group says that the $120-per-share share offer could work for Amgen only if it can attain 75% cost savings in sales and administration and 25% in R&D. That kind of cost savings looks impossible, given Amgen’s lack of experience in the hematological cancer market. And Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) has already rejected the $120 offer, so raising the bid would put further pressure on Amgen. If you are an Onyx shareholder, you shouldn’t pin much hope on Amgen.

So, who is the right fit?

After the rejection of Amgen, Inc. (NASDAQ:AMGN)’s unsolicited offer, there have been reports that large pharmaceutical companies are gearing up to enter the bidding war. Large firms are trying to boost their product portfolio and add new drugs to their pipeline as their major drugs go off patent. But I believe Bayer to be the best suitor for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).

Of Onyx’s $362 million revenues in 2012, 80% came from two drugs, Nexavar and Stivarga, sold in partnership with Bayer AG. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) gets 20% royalty on the sales of Stivarga, and 50-50 profit split on Nexavar.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

The 20 Biggest Contracts in MLB History

The 7 Worst Blown Calls in Sports History

7 Free Ways to Advertise Your Business Online

The 18 Best R&B Songs of the 90’s

The 10 Most Dangerous States to be a Cop

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!